Supplementation with fish oil increases first-line chemotherapy efficacy in patients with advanced nonsmall cell lung cancer

Cancer

Volumn 117, Issue 16, 2011, Pages 3774-3780

  Murphy, Rachel A ^a   Mourtzakis, Marina ^b   Chu, Quincy S C ^a   Baracos, Vickie E ^a   Reiman, Tony ^c   Mazurak, Vera C ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF WATERLOO   (Canada)

^c DALHOUSIE UNIVERSITY   (Canada)

Author keywords

carboplatin; lung cancer; n 3 fatty acids; response rate; survival; toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; DOCOSAHEXAENOIC ACID; FISH OIL; GEMCITABINE; ICOSATETRAENOIC ACID; NAVELBINE;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GASTRITIS; HAND FOOT SYNDROME; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; SIDE EFFECT; SYMPTOM; THROMBOCYTOPENIA; TREATMENT RESPONSE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; DIETARY SUPPLEMENTS; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; VINBLASTINE;

EID: 79960647676     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25933     Document Type: Article

References (38)

1. Canadian Cancer Society: Cancer Statistics. 2010. Toronto, Ontario: Canadian Cancer Society; 2010.
2. Kelly K, Crowley J, Bunn PA Jr, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol. 2001; 19: 3210-3218. (Pubitemid 32591438)
3. Schiller JH, Harrington D, Belani CP, et al. Comparison of 4 chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002; 346: 92-98. (Pubitemid 34438899)
4. Pujol JL, Barlesi F, Daures JP., Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials. Lung Cancer. 2006; 51: 335-345. (Pubitemid 43265817)
5. Carney DN., Lung cancer-time to move on from chemotherapy. N Engl J Med. 2002; 346: 126-128.
6. Hardman WE, Avula CP, Fernandes G, Cameron IL., Three percent dietary fish oil concentrate increased efficacy of doxorubicin against MDA-MB 231 breast cancer xenografts. Clin Cancer Res. 2001; 7: 2041-2049. (Pubitemid 32994843)
7. Hardman WE, Moyer MP, Cameron IL., Fish oil supplementation enhanced CPT-11 (irinotecan) efficacy against MCF7 breast carcinoma xenografts and ameliorated intestinal side-effects. Br J Cancer. 1999; 81: 440-448. (Pubitemid 29458797)
8. Jordan A, Stein J., Effect of an omega-3 fatty acid containing lipid emulsion alone and in combination with 5-fluorouracil (5-FU) on growth of the colon cancer cell line Caco-2. Eur J Nutr. 2003; 42: 324-331. (Pubitemid 38055612)
9. Germain E, Lavandier F, Chajes V, et al. Dietary n-3 polyunsaturated fatty acids and oxidants increase rat mammary tumor sensitivity to epirubicin without change in cardiac toxicity. Lipids. 1999; 34 (suppl): S203.
10. Yam D, Peled A, Shinitzky M., Suppression of tumor growth and metastasis by dietary fish oil combined with vitamins E and C and cisplatin. Cancer Chemother Pharmacol. 2001; 47: 34-40. (Pubitemid 32664510)
11. Biondo PD, Brindley DN, Sawyer MB, Field CJ., The potential for treatment with dietary long-chain polyunsaturated n-3 fatty acids during chemotherapy. J Nutr Biochem. 2008; 19: 787-796.
12. Baracos VE, Mazurak VC, Ma DW., n-3 Polyunsaturated fatty acids throughout the cancer trajectory: influence on disease incidence, progression, response to therapy and cancer-associated cachexia. Nutr Res Rev. 2004; 17: 177-192.
13. Xue H, Sawyer MB, Field CJ, Dieleman LA, Baracos VE., Nutritional modulation of antitumor efficacy and diarrhea toxicity related to irinotecan chemotherapy in rats bearing the ward colon tumor. Clin Cancer Res. 2007; 13: 7146-7154. (Pubitemid 350276901)
14. Hardman WE, Moyer MP, Cameron IL., Consumption of an omega-3 fatty acids product, INCELL AAFA, reduced side-effects of CPT-11 (irinotecan) in mice. Br J Cancer. 2002; 86: 983-988. (Pubitemid 34271037)
15. Bougnoux P, Hajjaji N, Ferrasson MN, Giraudeau B, Couet C, Le FO., Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: a phase II trial. Br J Cancer. 2009; 101: 1978-1985.
16. Murphy RA, Mourtzakis M, Chu QS, Baracos VE, Reiman T, Mazurak VC., Nutritional intervention with fish oil provides a benefit over standard of care on weight and skeletal muscle mass in non-small cell lung cancer patients receiving chemotherapy. Cancer. 2010. In Press.
17. Green FL, Page DL, Fleming ID, et al. American Joint Committee on Cancer Staging Manual. 6th ed. Philadelphia, Springer; 2002.
18. Fearon KC, Von Meyenfeldt MF, Moses AG, et al. Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial. Gut. 2003; 52: 1479-1486. (Pubitemid 37176729)
19. Fearon KC, Barber MD, Moses AG, et al. Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia. J Clin Oncol. 2006; 24: 3401-3407. (Pubitemid 46638896)
20. Bauer J, Capra S, Ferguson M., Use of the scored Patient-Generated Subjective Global Assessment (PG-SGA) as a nutrition assessment tool in patients with cancer. Eur J Clin Nutr. 2002; 56: 779-785.
21. Prado CM, Baracos VE, McCargar LJ, et al. Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res. 2007; 13: 3264-3268. (Pubitemid 46944911)
22. Antoun S, Baracos VE, Birdsell L, Escudier B, Sawyer MB., Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann Oncol. 2010; 21: 1594-1598.
23. Mourtzakis M, Prado CM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE., A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab. 2008; 33: 997-1006.
24. Shen W, Punyanitya M, Wang Z, et al. Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol. 2004; 97: 2333-2338. (Pubitemid 39552474)
25. Snyder WS, Cooke MJ, Mansett ES, Larhansen LT, Howells GP, Tipton IH., Report of the task group on reference man. 1974. Oxford, United Kingdom, Pergamon; 1974.
26. Murphy RA, Mourtzakis M, Chu QS, Reiman T, Mazurak VC., Skeletal muscle depletion is associated with reduced plasma (n-3) fatty acids in non-small cell lung cancer patients. J Nutr. 2010; 140: 1602-1606.
27. Pratt VC, Tredget EE, Clandinin MT, Field CJ., Fatty acid content of plasma lipids and erythrocyte phospholipids are altered following burn injury. Lipids. 2001; 36: 675-682. (Pubitemid 32777012)
28. Pratt VC, Tredget EE, Clandinin MT, Field CJ., Alterations in lymphocyte function and relation to phospholipid composition after burn injury in humans. Crit Care Med. 2002; 30: 1753-1761. (Pubitemid 34879586)
29. Pratt VC, Watanabe S, Bruera E, et al. Plasma and neutrophil fatty acid composition in advanced cancer patients and response to fish oil supplementation. Br J Cancer. 2002; 87: 1370-1378. (Pubitemid 36044310)
30. Baracos VE, Reiman T, Mourtzakis M, Gioulbasanis I, Antoun S., Body composition in patients with non-small cell lung cancer: a contemporary view of cancer cachexia with the use of computed tomography image analysis. Am J Clin Nutr. 2010; 91: 1133S-1137S.
31. Bougnoux P, Germain E, Chajes V, et al. Cytotoxic drug efficacy correlates with adipose tissue docosahexaenoic acid level in locally advanced breast carcinoma. Br J Cancer. 1999; 79: 1765-1769. (Pubitemid 29132302)
32. Dubey S, Schiller JH., Chemotherapy for advanced non-small cell lung cancer. Hematol Oncol Clin North Am. 2004; 18: 101-114. (Pubitemid 38201552)
33. Alberola V, Camps C, Provencio M, et al. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial. J Clin Oncol. 2003; 21: 3207-3213. (Pubitemid 46606251)
34. Murphy RA, Wilke MS, Perrine M, et al. Loss of adipose tissue and plasma phospholipids: relationship to survival in advanced cancer patients. Clin Nutr. 2010; 29: 482-487.
35. Gogos CA, Ginopoulos P, Salsa B, Apostolidou E, Zoumbos NC, Kalfarentzos F., Dietary omega-3 polyunsaturated fatty acids plus vitamin E restore immunodeficiency and prolong survival for severely ill patients with generalized malignancy: a randomized control trial. Cancer. 1998; 82: 395-402. (Pubitemid 28060258)
36. Germain E, Bonnet P, Aubourg L, Grangeponte MC, Chajes V, Bougnoux P., Anthracycline-induced cardiac toxicity is not increased by dietary omega-3 fatty acids. Pharmacol Res. 2003; 47: 111-117. (Pubitemid 36263445)
37. Horie T, Nakamaru M, Masubuchi Y., Docosahexaenoic acid exhibits a potent protection of small intestine from methotrexate-induced damage in mice. Life Sci. 1998; 62: 1333-1338. (Pubitemid 28177431)
38. Gomez De Segura IA, Valderrabano S, Vazquez I, et al. Protective effects of dietary enrichment with docosahexaenoic acid plus protein in 5-fluorouracil-induced intestinal injury in the rat. Eur J Gastroenterol Hepatol. 2004; 16: 479-485. (Pubitemid 38586477)